No ano passado, Eli Lilly and Co gerou US$ 11.54B em seu segmento de melhor desempenho, Diabetes-Mounjaro. A região U.S. teve a maior contribuição, com US$ 43.48B no período. No último trimestre, Eli Lilly and Co registrou receita de US$ 9.94B no período encerrado em 2026-06-30, proveniente principalmente do segmento Diabetes-Mounjaro. A região U.S. teve a maior contribuição, com receita de US$ 14.41B.

Por Empresa

Receita

Proporção

Anual

Anual

Trimestral

Diabetes-Mounjaro

Oncology-Verzenio

Diabetes-Trulicity

Diabetes-Zepbound

Diabetes-Jardiance

Immunology-Taltz

Diabetes-Humalog

Oncology-Other Oncology

Oncology-Cyramza

Immunology-Olumiant

Diabetes-Humulin

Other-Other

Neuroscience-Emgality

Diabetes-Basaglar

Oncology-Erbitux

Oncology-Tyvyt

Diabetes-Other Diabetes

Neuroscience-Other Neuroscience

Immunology-Other Immunology

Neuroscience-Zyprexa

Diabetes-Baqsimi

Other-Forteo

Other-Cialis

Oncology-Alimta

Other-COVID-19 Antibodies

Neuroscience-Cymbalta

Diabetes-Trajenta

Other Bamlanivimab

Endocrinology-Trulicity

Endocrinology-Humalog

Endocrinology-Forteo

Endocrinology-Humulin

Endocrinology-Basaglar

Endocrinology-Jardiance

Endocrinology-Trajenta

Endocrinology-Olumiant

Neuroscience-Strattera

Product

Collaborationand Other Revenue

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Diabetes-Mounjaro

11.54B(25.62%)

5.16B(15.13%)

482.50M(1.69%)

--(--)

Oncology-Verzenio

5.31B(11.78%)

3.86B(11.32%)

2.48B(8.70%)

1.35B(4.77%)

912.60M(3.72%)

579.70M(2.60%)

--(--)

Diabetes-Trulicity

5.25B(11.66%)

7.13B(20.90%)

7.44B(26.07%)

6.47B(22.85%)

5.07B(20.65%)

--(--)

Diabetes-Zepbound

4.93B(10.94%)

175.80M(0.52%)

--(--)

Diabetes-Jardiance

3.34B(7.42%)

2.74B(8.04%)

2.07B(7.24%)

1.49B(5.26%)

1.15B(4.70%)

--(--)

Immunology-Taltz

3.26B(7.24%)

2.76B(8.09%)

2.48B(8.70%)

2.21B(7.81%)

1.79B(7.29%)

1.37B(6.12%)

--(--)

Diabetes-Humalog

2.32B(5.16%)

1.66B(4.87%)

2.06B(7.22%)

2.45B(8.66%)

2.63B(10.70%)

--(--)

Oncology-Other Oncology

1.32B(2.93%)

612.90M(1.80%)

423.80M(1.48%)

330.80M(1.17%)

507.60M(2.07%)

450.30M(2.02%)

--(--)

Oncology-Cyramza

973.20M(2.16%)

974.70M(2.86%)

971.40M(3.40%)

1.03B(3.65%)

1.03B(4.21%)

925.20M(4.15%)

--(--)

Immunology-Olumiant

957.40M(2.13%)

922.70M(2.70%)

830.50M(2.91%)

1.12B(3.94%)

638.80M(2.60%)

--(--)

Diabetes-Humulin

917.10M(2.04%)

852.10M(2.50%)

1.02B(3.57%)

1.22B(4.32%)

1.26B(5.13%)

--(--)

Other-Other

903.00M(2.00%)

207.60M(0.61%)

295.50M(1.04%)

370.00M(1.31%)

568.20M(2.32%)

483.90M(2.17%)

--(--)

Neuroscience-Emgality

870.40M(1.93%)

678.20M(1.99%)

650.90M(2.28%)

577.20M(2.04%)

362.90M(1.48%)

162.60M(0.73%)

--(--)

Diabetes-Basaglar

676.90M(1.50%)

728.30M(2.13%)

760.40M(2.66%)

892.50M(3.15%)

1.12B(4.58%)

--(--)

Oncology-Erbitux

627.40M(1.39%)

596.50M(1.75%)

566.50M(1.98%)

548.20M(1.94%)

536.40M(2.19%)

543.30M(2.43%)

--(--)

Oncology-Tyvyt

526.00M(1.17%)

393.40M(1.15%)

293.30M(1.03%)

418.10M(1.48%)

--(--)

Diabetes-Other Diabetes

512.70M(1.14%)

530.20M(1.55%)

636.20M(2.23%)

284.80M(1.01%)

244.00M(0.99%)

--(--)

Neuroscience-Other Neuroscience

486.70M(1.08%)

505.50M(1.48%)

275.10M(0.96%)

309.50M(1.09%)

294.10M(1.20%)

173.80M(0.78%)

--(--)

Immunology-Other Immunology

175.10M(0.39%)

115.20M(0.34%)

32.10M(0.11%)

32.90M(0.12%)

34.60M(0.14%)

426.90M(1.91%)

--(--)

Neuroscience-Zyprexa

116.30M(0.26%)

1.69B(4.97%)

336.90M(1.18%)

430.30M(1.52%)

406.60M(1.66%)

418.60M(1.88%)

--(--)

Diabetes-Baqsimi

29.20M(0.06%)

677.60M(1.99%)

--(--)

Other-Forteo

--(--)

533.20M(1.56%)

613.10M(2.15%)

801.90M(2.83%)

1.05B(4.26%)

--(--)

Other-Cialis

--(--)

381.40M(1.12%)

587.30M(2.06%)

718.50M(2.54%)

607.20M(2.47%)

890.50M(3.99%)

--(--)

Oncology-Alimta

--(--)

217.50M(0.64%)

927.70M(3.25%)

2.06B(7.28%)

2.33B(9.49%)

2.12B(9.48%)

--(--)

Other-COVID-19 Antibodies

--(--)

2.02B(7.09%)

2.24B(7.91%)

--(--)

Neuroscience-Cymbalta

--(--)

283.30M(0.99%)

581.50M(2.05%)

767.70M(3.13%)

725.40M(3.25%)

--(--)

Diabetes-Trajenta

--(--)

372.50M(1.32%)

358.60M(1.46%)

--(--)

Other Bamlanivimab

--(--)

871.20M(3.55%)

--(--)

Endocrinology-Trulicity

--(--)

4.13B(18.49%)

--(--)

Endocrinology-Humalog

--(--)

2.82B(12.64%)

--(--)

Endocrinology-Forteo

--(--)

1.40B(6.29%)

--(--)

Endocrinology-Humulin

--(--)

1.29B(5.78%)

--(--)

Endocrinology-Basaglar

--(--)

1.11B(4.98%)

--(--)

Endocrinology-Jardiance

--(--)

944.20M(4.23%)

--(--)

Endocrinology-Trajenta

--(--)

590.60M(2.65%)

--(--)

Endocrinology-Olumiant

--(--)

523.80M(2.35%)

--(--)

Neuroscience-Strattera

--(--)

242.50M(1.09%)

--(--)

Product

--(--)

22.93B(93.37%)

Collaborationand Other Revenue

--(--)

1.63B(6.63%)

Por Região

Receita

Proporção

Anual

Anual

Trimestral

U.S.

Europe

Other foreign countries

Japan

China

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

U.S.

43.48B(66.71%)

30.38B(67.44%)

21.79B(63.86%)

18.19B(63.73%)

16.81B(59.36%)

14.23B(57.98%)

12.72B(57.00%)

12.39B(57.65%)

11.41B(57.15%)

11.51B(54.22%)

10.10B(50.59%)

9.13B(46.57%)

12.89B(55.77%)

12.31B(54.47%)

12.98B(53.43%)

Europe

11.56B(17.73%)

6.92B(15.36%)

6.17B(18.09%)

4.30B(15.06%)

4.78B(16.87%)

4.19B(17.06%)

3.77B(16.87%)

3.66B(17.04%)

3.39B(16.98%)

3.77B(17.76%)

3.94B(19.76%)

4.51B(22.98%)

4.34B(18.77%)

4.26B(18.85%)

5.29B(21.79%)

Other foreign countries

6.06B(9.29%)

4.27B(9.48%)

2.95B(8.63%)

2.85B(9.99%)

2.70B(9.54%)

2.42B(9.87%)

3.28B(14.71%)

3.03B(14.10%)

2.83B(14.17%)

3.62B(17.04%)

3.88B(19.46%)

3.95B(20.13%)

3.82B(16.53%)

3.78B(16.74%)

3.91B(16.12%)

Japan

2.13B(3.27%)

1.81B(4.03%)

1.67B(4.90%)

1.75B(6.12%)

2.37B(8.36%)

2.58B(10.53%)

2.55B(11.41%)

2.41B(11.20%)

2.34B(11.71%)

2.33B(10.98%)

2.03B(10.19%)

2.03B(10.33%)

2.06B(8.93%)

2.25B(9.94%)

2.10B(8.66%)

China

1.95B(2.99%)

1.66B(3.69%)

1.54B(4.51%)

1.45B(5.09%)

1.66B(5.87%)

1.12B(4.55%)

--(--)